7291-41-0 Usage
Uses
Used in Pharmaceutical Industry:
Estra-1,3,5(10),6-tetraene-3,17-diol is used as a pharmaceutical agent for its potential therapeutic effects. Due to its structural similarity to 17beta-estradiol, it may have applications in hormone-related treatments and interventions.
Used in Research Applications:
Estra-1,3,5(10),6-tetraene-3,17-diol is utilized as a research compound for studying the effects of steroid hormones and their analogs on various biological processes. Its unique structure allows scientists to investigate its interactions with hormone receptors and signaling pathways, potentially leading to the development of new therapeutic agents.
Used in Hormone Replacement Therapy:
Estra-1,3,5(10),6-tetraene-3,17-diol may be used as a component in hormone replacement therapy, particularly for conditions that require the modulation of estrogen levels. Its specific properties could make it a valuable option for patients seeking alternative treatments to conventional hormone therapies.
Used in Drug Development:
The unique structure and biological activity of estra-1,3,5(10),6-tetraene-3,17-diol make it a promising candidate for drug development. Researchers can explore its potential as a lead compound for the creation of new medications targeting various health conditions, including hormone-related disorders and diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 7291-41-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,2,9 and 1 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 7291-41:
(6*7)+(5*2)+(4*9)+(3*1)+(2*4)+(1*1)=100
100 % 10 = 0
So 7291-41-0 is a valid CAS Registry Number.
InChI:InChI=1/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h2-5,10,14-17,19-20H,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1
7291-41-0Relevant academic research and scientific papers
Cytoprotective steroids (II)
-
, (2008/06/13)
A method is provided for treating a patient in need of therapy for acute neuronal degeneration due to metabolic compromise of central or peripheral nervous system cells comprising administering to that patient a therapeutically effective amount of a 7α-hydroxy substituted steroid selected from 7α-hydroxy-derivatives of estradiols, dehydroepiandrosterones and pregnenolones, and metabolic precursors thereof. Use of such compounds for manufacture of medicaments and neuroprotective compositions are also provided.
New synthesis of Δ6-estrogens
Rao, Pemmaraju N.,Wang, Zhiqiang
, p. 487 - 490 (2007/10/03)
An efficient approach to synthesize Δ6-estrogens is described. The key steps in the synthesis are the introduction of a hydroxyl group at the Δ6 position of a suitably protected estrogen using a superbase and subsequent dehydration with Martin sulfurane reagent or methyltriphenoxyphosphonium iodide. The two-step synthetic procedure readily gave the Δ6-estrogens in high yield.
An Efficient Preparation of 6,7-Didehydroestrogenes
Ciattini, Pier Giuseppe,Morera, Enrico,Ortar, Giorgio
, p. 1293 - 1297 (2007/10/02)
The title compounds are prepared in excellent yield by palladium-catalyzed reduction with triethylammonium formate of enol triflates of 6-oxo-estrogens.
IMPROVED PREPARATION OF 3,17β-DIHYDROXYOESTRA-1,3,5(10),6-TETRAENE
Gill, Julie C.,Marples, Brian A.,Traynor, John R.
, p. 155 - 158 (2007/10/02)
The title compound is prepared in good yield via the tosylhydrazone of 3,17β-diacetoxyoestra-1,3,5(10)-triene-6-one (Shapiro reaction)
